Ftse Mib
34.165,92
0,01%
DAX
19.909,14
-0,25%
S&P 500
5.934,97
-0,60%
NASDAQ
19.600,82
-0,61%
Bitcoin
94.320,37
0,88%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ MIRA Pharmaceuticals Inc (MIRA) MIRA Pharmaceuticals Inc (MIRA) Notizie

MIRA Pharmaceuticals Inc

MIRA
1,15
-0,03 (-2,54%)
Ultimo aggiornamento: 19:13:55
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/12/202423:00EDGAR2Form 8-K - Current report
19/12/202414:30EDGAR2Form 8-K - Current report
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/12/202414:45EDGAR2Form 8-K - Current report
27/11/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202422:15EDGAR2Form 3 - Initial statement of beneficial ownership of..
21/11/202422:15EDGAR2Form 8-K - Current report
19/11/202423:58EDGAR2Form 144 - Report of proposed sale of securities
19/11/202422:10EDGAR2Form 8-K - Current report
12/11/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
25/10/202422:01EDGAR2Form 8-K - Current report
21/10/202413:00EDGAR2Form 8-K - Current report
27/9/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/9/202422:45EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/9/202422:30EDGAR2Form 8-K - Current report
10/9/202422:01EDGAR2Form 8-K - Current report
05/9/202402:20EDGAR2Form 144 - Report of proposed sale of securities
30/8/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/8/202414:58IHMARKETNEWSIBM Closes China Research Division, Uber Fined $324M,..
23/8/202422:15EDGAR2Form 8-K - Current report
16/8/202422:05EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
13/8/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202414:37EDGAR2Form S-3 - Registration statement under Securities Act of..
09/8/202422:13EDGAR2Form 8-K - Current report
08/8/202414:54EDGAR2Form 8-K - Current report
26/7/202422:55EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/7/202422:49EDGAR2Form DEF 14A - Other definitive proxy statements
24/7/202422:07EDGAR2Form 8-K - Current report
19/7/202423:12EDGAR2Form 8-K - Current report
12/7/202423:00EDGAR2Form 8-K - Current report
24/6/202414:30PRNUSMIRA Pharmaceuticals Announces Ketamir-2 Shows Promising..
10/6/202414:30PRNUSMira Pharmaceuticals Announces Positive Preclinical Study..
31/5/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202414:45PRNUSMira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel..
29/5/202414:30EDGAR2Form 8-K - Current report
22/5/202423:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202414:45PRNUSMIRA Pharmaceuticals in Discussions with Memorial Sloan..
20/5/202414:00PRNUSMira Pharmaceuticals Advances Preclinical Trials Towards an..
13/5/202422:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/4/202414:00PRNUSMira Pharmaceuticals Announces Encouraging Preclinical..
21/3/202416:04PRNUSMIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head..
07/3/202422:45EDGAR2Form 8-K - Current report
05/2/202414:30PRNUSMIRA Pharmaceuticals Provides Corporate Update
17/1/202422:30EDGAR2Form 8-K - Current report
Apertura: 1,172 Min: 1,09 Max: 1,172
Chiusura: 1,18

La tua Cronologia

NASDAQ
MIRA
MIRA Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network